Emerging and established clinical, histopathological and molecular parametric prognostic factors for metastatic spine disease secondary to lung cancer

Helping surgeons make decisions

Nuno Batista, Jin Tee, Daniel Sciubba, Arjun Sahgal, Ilya Laufer, Michael Weber, Ziya Gokaslan, Laurence Rhines, Michael Fehlings, Shreyaskumar Patel, Y. Raja Rampersaud, Jeremy Reynolds, Dean Chou, Chetan Bettegowda, Michelle Clarke, Charles Fisher

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Metastatic lung cancer to the spine occurs at high rates with patients usually given poor prognoses. Recent studies have observed that patients with certain genetic and molecular aberrations have better responses to adjuvant therapy. As such, current metastatic spine disease treatment algorithms grading all lung primaries’ prognosis as poor may lead to inadequate treatment of spinal metastases. The aims of this study are to determine current survival patterns in 
metastatic spine disease secondary to lung cancer and identify relevant parameters that influence the prognostication of these patients. A systematic review in accordance with PRISMA guidelines was conducted for literature published between January 1, 1996 and September 31, 2015. The 27 studies identified were Level IV retrospective studies with an overall ‘low’ level of evidence. The overall median survival of patients with spine involved metastatic lung cancer was poor, ranging from 3.6 to 9 months. Median survival of patients with non-small cell lung cancer being treated with epidermal growth factor receptor (EGFR) inhibitors were observed to be better, with survival of up to 18 months. This review reports a subset of lung cancer patients with oncogenic molecular mutations that appear to confer a better overall survival. In these patients, individualized assessment rather than strict adherence to current metastatic scoring algorithms when determining management may be preferred.

Original languageEnglish (US)
Pages (from-to)15-22
Number of pages8
JournalJournal of Clinical Neuroscience
Volume34
DOIs
StatePublished - Dec 1 2016

Fingerprint

Lung Neoplasms
Spine
Survival
Surgeons
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Molecular Biology
Therapeutics
Retrospective Studies
Guidelines
Neoplasm Metastasis
Lung
Mutation

Keywords

  • Adjuvant therapy
  • ALK
  • EGFR
  • Genetic markers
  • Lung cancer
  • Metastatic spine disease

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Physiology (medical)

Cite this

Emerging and established clinical, histopathological and molecular parametric prognostic factors for metastatic spine disease secondary to lung cancer : Helping surgeons make decisions. / Batista, Nuno; Tee, Jin; Sciubba, Daniel; Sahgal, Arjun; Laufer, Ilya; Weber, Michael; Gokaslan, Ziya; Rhines, Laurence; Fehlings, Michael; Patel, Shreyaskumar; Raja Rampersaud, Y.; Reynolds, Jeremy; Chou, Dean; Bettegowda, Chetan; Clarke, Michelle; Fisher, Charles.

In: Journal of Clinical Neuroscience, Vol. 34, 01.12.2016, p. 15-22.

Research output: Contribution to journalReview article

Batista, N, Tee, J, Sciubba, D, Sahgal, A, Laufer, I, Weber, M, Gokaslan, Z, Rhines, L, Fehlings, M, Patel, S, Raja Rampersaud, Y, Reynolds, J, Chou, D, Bettegowda, C, Clarke, M & Fisher, C 2016, 'Emerging and established clinical, histopathological and molecular parametric prognostic factors for metastatic spine disease secondary to lung cancer: Helping surgeons make decisions', Journal of Clinical Neuroscience, vol. 34, pp. 15-22. https://doi.org/10.1016/j.jocn.2016.05.023
Batista, Nuno ; Tee, Jin ; Sciubba, Daniel ; Sahgal, Arjun ; Laufer, Ilya ; Weber, Michael ; Gokaslan, Ziya ; Rhines, Laurence ; Fehlings, Michael ; Patel, Shreyaskumar ; Raja Rampersaud, Y. ; Reynolds, Jeremy ; Chou, Dean ; Bettegowda, Chetan ; Clarke, Michelle ; Fisher, Charles. / Emerging and established clinical, histopathological and molecular parametric prognostic factors for metastatic spine disease secondary to lung cancer : Helping surgeons make decisions. In: Journal of Clinical Neuroscience. 2016 ; Vol. 34. pp. 15-22.
@article{cda1120a13a6457e8e279af80890c55f,
title = "Emerging and established clinical, histopathological and molecular parametric prognostic factors for metastatic spine disease secondary to lung cancer: Helping surgeons make decisions",
abstract = "Metastatic lung cancer to the spine occurs at high rates with patients usually given poor prognoses. Recent studies have observed that patients with certain genetic and molecular aberrations have better responses to adjuvant therapy. As such, current metastatic spine disease treatment algorithms grading all lung primaries’ prognosis as poor may lead to inadequate treatment of spinal metastases. The aims of this study are to determine current survival patterns in 
metastatic spine disease secondary to lung cancer and identify relevant parameters that influence the prognostication of these patients. A systematic review in accordance with PRISMA guidelines was conducted for literature published between January 1, 1996 and September 31, 2015. The 27 studies identified were Level IV retrospective studies with an overall ‘low’ level of evidence. The overall median survival of patients with spine involved metastatic lung cancer was poor, ranging from 3.6 to 9 months. Median survival of patients with non-small cell lung cancer being treated with epidermal growth factor receptor (EGFR) inhibitors were observed to be better, with survival of up to 18 months. This review reports a subset of lung cancer patients with oncogenic molecular mutations that appear to confer a better overall survival. In these patients, individualized assessment rather than strict adherence to current metastatic scoring algorithms when determining management may be preferred.",
keywords = "Adjuvant therapy, ALK, EGFR, Genetic markers, Lung cancer, Metastatic spine disease",
author = "Nuno Batista and Jin Tee and Daniel Sciubba and Arjun Sahgal and Ilya Laufer and Michael Weber and Ziya Gokaslan and Laurence Rhines and Michael Fehlings and Shreyaskumar Patel and {Raja Rampersaud}, Y. and Jeremy Reynolds and Dean Chou and Chetan Bettegowda and Michelle Clarke and Charles Fisher",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.jocn.2016.05.023",
language = "English (US)",
volume = "34",
pages = "15--22",
journal = "Journal of Clinical Neuroscience",
issn = "0967-5868",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Emerging and established clinical, histopathological and molecular parametric prognostic factors for metastatic spine disease secondary to lung cancer

T2 - Helping surgeons make decisions

AU - Batista, Nuno

AU - Tee, Jin

AU - Sciubba, Daniel

AU - Sahgal, Arjun

AU - Laufer, Ilya

AU - Weber, Michael

AU - Gokaslan, Ziya

AU - Rhines, Laurence

AU - Fehlings, Michael

AU - Patel, Shreyaskumar

AU - Raja Rampersaud, Y.

AU - Reynolds, Jeremy

AU - Chou, Dean

AU - Bettegowda, Chetan

AU - Clarke, Michelle

AU - Fisher, Charles

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Metastatic lung cancer to the spine occurs at high rates with patients usually given poor prognoses. Recent studies have observed that patients with certain genetic and molecular aberrations have better responses to adjuvant therapy. As such, current metastatic spine disease treatment algorithms grading all lung primaries’ prognosis as poor may lead to inadequate treatment of spinal metastases. The aims of this study are to determine current survival patterns in 
metastatic spine disease secondary to lung cancer and identify relevant parameters that influence the prognostication of these patients. A systematic review in accordance with PRISMA guidelines was conducted for literature published between January 1, 1996 and September 31, 2015. The 27 studies identified were Level IV retrospective studies with an overall ‘low’ level of evidence. The overall median survival of patients with spine involved metastatic lung cancer was poor, ranging from 3.6 to 9 months. Median survival of patients with non-small cell lung cancer being treated with epidermal growth factor receptor (EGFR) inhibitors were observed to be better, with survival of up to 18 months. This review reports a subset of lung cancer patients with oncogenic molecular mutations that appear to confer a better overall survival. In these patients, individualized assessment rather than strict adherence to current metastatic scoring algorithms when determining management may be preferred.

AB - Metastatic lung cancer to the spine occurs at high rates with patients usually given poor prognoses. Recent studies have observed that patients with certain genetic and molecular aberrations have better responses to adjuvant therapy. As such, current metastatic spine disease treatment algorithms grading all lung primaries’ prognosis as poor may lead to inadequate treatment of spinal metastases. The aims of this study are to determine current survival patterns in 
metastatic spine disease secondary to lung cancer and identify relevant parameters that influence the prognostication of these patients. A systematic review in accordance with PRISMA guidelines was conducted for literature published between January 1, 1996 and September 31, 2015. The 27 studies identified were Level IV retrospective studies with an overall ‘low’ level of evidence. The overall median survival of patients with spine involved metastatic lung cancer was poor, ranging from 3.6 to 9 months. Median survival of patients with non-small cell lung cancer being treated with epidermal growth factor receptor (EGFR) inhibitors were observed to be better, with survival of up to 18 months. This review reports a subset of lung cancer patients with oncogenic molecular mutations that appear to confer a better overall survival. In these patients, individualized assessment rather than strict adherence to current metastatic scoring algorithms when determining management may be preferred.

KW - Adjuvant therapy

KW - ALK

KW - EGFR

KW - Genetic markers

KW - Lung cancer

KW - Metastatic spine disease

UR - http://www.scopus.com/inward/record.url?scp=84995922739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995922739&partnerID=8YFLogxK

U2 - 10.1016/j.jocn.2016.05.023

DO - 10.1016/j.jocn.2016.05.023

M3 - Review article

VL - 34

SP - 15

EP - 22

JO - Journal of Clinical Neuroscience

JF - Journal of Clinical Neuroscience

SN - 0967-5868

ER -